International normalized ratio decreases after hemodialysis treatment in patients treated with warfarin

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 6, 2012, Pages 502-507

  Abe, Masanori ^a   Maruyama, Noriaki ^a   Suzuki, Hiroko ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

hemodialysis; international normalized ratio; warfarin

Indexed keywords

ALBUMIN; WARFARIN;

AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISOMER; MALE; PRIORITY JOURNAL;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA VOLUME; PROTEIN BINDING; RENAL DIALYSIS; SERUM ALBUMIN; TIME FACTORS; WARFARIN;

EID: 84871530637     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826f34f3     Document Type: Article

References (28)

1. Estes NA III, Halperin JL, Calkins H, et al; and American College of Cardiology; American Heart Association Task Force on Performance Measures Physician; Consortium for Performance Improvement. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol. 2008;51:865-884.
2. Fuster V, Rydén LE, Cannom DS, et al; and European Heart Rhythm Association; Heart Rhythm Society, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906.
3. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-2292.
4. Chan KE, Lazarus JM, Thadhani R, et al. Anticoagulant and antiplatelet usage associates with mortality among HD patients. J Am Soc Nephrol. 2009;20:872-881.
5. Bennett WM. Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol. 2006;1:1357-1359.
6. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20: 705-711.
7. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associated with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233.
8. Sood MM, Komenda P, Sood AR, et al. The intersection of risk and benefit: is warfarin anticoafulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136:1128-1133.
9. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharamacokinetic consideration in the control of oral anticoagulant therapy. Clin Pharacokinet. 1989;16:238-253.
10. Matsumoto K, Ishida S, Ueno K, et al. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol. 2001;41:459-464.
11. O'Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, eds. The New Dimensions of Warfarin Prophylaxis: Advances in Experimental Medicine and Biology. New York, NY: Plenum; 1986:205-212.
12. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol. 1978;15:19-26.
13. O'Reilly RA. Vitamin K and other oral anticoagulant drugs. Annu Rev Med. 1976;27:245-261.
14. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet. 1979;4:1-15.
15. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983;3: 155-193.
16. Ganeval D, Fischer AM, Barre J, et al. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol. 1986;25:75-80.
17. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Drug Saf. 1997;16:205-231.
18. Rolan PE. Plasma protein binding displacement interaction; why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37: 125-128.
19. Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64: 603-609.
20. Toyoda K, Fujii K, Fujimi S, et al, IidaM. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005;45:1058-1066.
21. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-1711.
22. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974;15:424-430.
23. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974;16:348-354.
24. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986;39: 15-24.
25. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976;295:354-357.
26. O'Reilly RA. Stereoselective interaction of trimethoprim-aulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med. 1980;302:33-35.
27. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974;53:1607-1617.
28. O'Reilly RA, Trager WF, Rettie AE, et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther. 1987;42:290-294.